Clinical analysis of primary gastrointestinal non-hodgkin's lymphoma
Pakistan Journal of Medical Sciences. 2017; 33 (6): 1406-1411
em En
| IMEMR
| ID: emr-189396
Biblioteca responsável:
EMRO
Objective: To study the clinical characteristics and prognostic factors of survival for patients with primary gastrointestinal non-Hodgkin's lymphoma [PGI-NHL]
Methods: A retrospective analysis was performed for 104 PGI-NHL patients who were admitted in Baoding First Central Hospital from July 2003 to January 2014
Results: There were 58 males and 46 females. The median age of onset was 53 [15-83] years old. In terms of pathogenic sites, there were 51 gastric cases [49.00%] and 53 intestinal cases [51.00%], with the median survival of 35 [1-130] months. The 1-, 3- and 5-year overall survival [OS] rates were 88.40%, 80.70% and 78.80%, respectively. The factors influencing the progression-free survival [PFS] and OS rates were studied by univariate and multivariate analyses. The PFS and OS rates of patients with B-cell PGI-NHL were significantly higher than those of patients with T-cell PGI-NHL [P<0.05]. The PFS and OS rates of patients with primary gastric lymphoma were significantly higher than those of patients with primary intestinal lymphoma [P<0.05], but the data were not associated with Ann Arbor stage or LDH level [P>0.05]. Compared with non-surgical patients, only patients with intestinal lymphoma benefited from surgery [P<0.05]
Conclusion: The pathogenic site and pathological type are risk factors that affect the survival of PGI-NHL patients, and chemotherapy should be given the first priority for patients with primary gastric lymphoma
Methods: A retrospective analysis was performed for 104 PGI-NHL patients who were admitted in Baoding First Central Hospital from July 2003 to January 2014
Results: There were 58 males and 46 females. The median age of onset was 53 [15-83] years old. In terms of pathogenic sites, there were 51 gastric cases [49.00%] and 53 intestinal cases [51.00%], with the median survival of 35 [1-130] months. The 1-, 3- and 5-year overall survival [OS] rates were 88.40%, 80.70% and 78.80%, respectively. The factors influencing the progression-free survival [PFS] and OS rates were studied by univariate and multivariate analyses. The PFS and OS rates of patients with B-cell PGI-NHL were significantly higher than those of patients with T-cell PGI-NHL [P<0.05]. The PFS and OS rates of patients with primary gastric lymphoma were significantly higher than those of patients with primary intestinal lymphoma [P<0.05], but the data were not associated with Ann Arbor stage or LDH level [P>0.05]. Compared with non-surgical patients, only patients with intestinal lymphoma benefited from surgery [P<0.05]
Conclusion: The pathogenic site and pathological type are risk factors that affect the survival of PGI-NHL patients, and chemotherapy should be given the first priority for patients with primary gastric lymphoma
Buscar no Google
Índice:
IMEMR
Tipo de estudo:
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Pak. J. Med. Sci.
Ano de publicação:
2017